Laparoscopic Retroperitoneal Lymph Node Dissection
Authors:
- Reinhard PeschelRPReinhard Peschel
- Alfred HobischAHAlfred Hobisch
- Georg BartschGBGeorg Bartsch
- 1 May 2001
- journal article
- research article
- Published by SAGE Publications in Journal of Endourology
- Vol. 15 (4) , 449-455
Abstract
Purpose: Retroperitoneal lymph node dissection is the most sensitive and specific diagnostic modality for detecting occult lymph node metastases in clinical stage I testicular tumor. In stage II disease, residual tumors after chemotherapy have to be removed surgically. To reduce the morbidity of these procedures we have replaced open surgery by laparoscopy. Patients and Methods: Between August 1992 and December 1999 125 patients underwent laparoscopic RPLND (stage I: 76 pts., stage II: 49 pts.) Results: Laparoscopic RPLND could be completed as planned in all but two patients in whom bleeding required conversion to open surgery. Once the learning curve had been overcome, mean operative time decreased significantly from 476 to 219 min for stage I and averaged 226 min in stage IIB disease. Only minor postoperative complications occurred such as asymptomatic lymphoceles (7 pts.) and chylous ascites (6 pts.). Mean post-op hospital stay was 3.3 and 3.5 days, respectively (stages I and II). Mean followup is currently 46 months for stage I and 35 months for stage II tumors. Over this period a single retroperitoneal recurrence was observed (stage I), which, however, was not due to surgical failure, but to false negative histologic findings. All other patients have remained free of relapse. Conclusions: Laparoscopic RPLND is a demanding procedure with a long and steep learning curve. It has proved feasible also after chemotherapy. The diagnostic accuracy of laparoscopic RPLND was as good as that of the open procedure, while the morbidity is significantly lower. Tumor control was not compromised by the laparoscopic approach.Keywords
This publication has 27 references indexed in Scilit:
- RISK OF SYSTEMIC METASTASES IN CLINICAL STAGE I NONSEMINOMA GERM CELL TESTIS TUMOR MANAGED BY RETROPERITONEAL LYMPH NODE DISSECTIONJournal of Urology, 2000
- QUALITY OF LIFE AFTER LAPAROSCOPIC VERSUS OPEN RETROPERITONEAL LYMPHADENECTOMY FOR TESTICULAR TUMOR - THE PATIENTS' VIEWJournal of Urology, 1999
- LONG-TERM RESULTS FOLLOWING ADJUVANT CHEMOTHERAPY IN PATIENTS WITH CLINICAL STAGE I TESTICULAR NONSEMINOMATOUS MALIGNANT GERM CELL TUMORS WITH HIGH RISK FACTORSJournal of Urology, 1999
- LAPAROSCOPIC RETROPERITONEAL LYMPHADENECTOMY AFTER CHEMOTHERAPY FOR STAGE IIB NONSEMINOMATOUS TESTICULAR CARCINOMAJournal of Urology, 1999
- Retroperitoneal Lymphadenectomy for Clinical Stage I Nonseminomatous Testicular Tumor: Laparoscopy Versus Open Surgery and Impact of Learning CurveJournal of Urology, 1996
- Cost and quality-of-life analyses of surgery for early endometrial cancer: Laparotomy versus laparoscopyAmerican Journal of Obstetrics and Gynecology, 1996
- A Surveillance Study of Clinical Stage I Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1995
- The Role of Retroperitoneal Lymphadenectomy in Clinical Stage B Testis Cancer: The Indiana University Experience (1965 to 1989)Journal of Urology, 1995
- Immediate Adjuvant Chemotherapy versus Observation with Treatment at Relapse in Pathological Stage II Testicular CancerNew England Journal of Medicine, 1987
- Clinical Stage II Non‐seminomatous Germ Cell Testicular Tumours. Results of Management by Primary ChemotherapyBritish Journal of Urology, 1985